Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer

scientific article published on 16 January 2007

Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1026106232
P356DOI10.1038/SJ.TPJ.6500434
P698PubMed publication ID17224914

P50authorTimothy SynoldQ78536675
P2093author name stringX Li
H L McLeod
C R King
P Frankel
G Somlo
W D Shannon
S Marsh
P2860cites workmdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapyQ27824862
The orphan nuclear receptor SXR coordinately regulates drug metabolism and effluxQ28186424
The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissueQ28214188
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan dispositionQ33206580
???Q28366611
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoQ35113118
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experienceQ35783180
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic interventionQ36425250
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancerQ36623452
ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecinsQ40568208
Increased transcriptional activity of the CYP3A4*1B promoter variantQ40607751
Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolismQ40760221
Identification of functionally variant MDR1 alleles among European Americans and African AmericansQ43705904
Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozymeQ44183995
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotypeQ44960521
CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, ItalyQ45185406
Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancerQ45285506
Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian populationQ45712938
CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populationsQ46464296
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicityQ46923500
Catalytic properties of polymorphic human cytochrome P450 1B1 variantsQ50125350
Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.Q54684767
CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian CancerQ61608137
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomesQ63241956
Expression of cytochrome P450 CYP1B1 in breast cancerQ71816201
Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controlsQ73548231
Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiolQ73914185
The genetic determinants of the CYP3A5 polymorphismQ77341911
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysisQ79297590
Drug pathways: moving beyond single gene pharmacogeneticsQ79768663
ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancerQ79834519
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxelQ81506947
Taxane pharmacogeneticsQ88759446
P433issue5
P921main subjectbreast cancerQ128581
paclitaxelQ423762
P304page(s)362-365
P577publication date2007-01-16
P1433published inThe Pharmacogenomics JournalQ10534704
P1476titlePharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer
P478volume7

Reverse relations

cites work (P2860)
Q47157497Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results
Q34936845CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro
Q37055326CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
Q33704464Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
Q35003605Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies
Q86451186Differentially expressed proteins in human MCF-7 breast cancer cells sensitive and resistant to paclitaxel
Q35823740ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors
Q36550926Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer
Q37811967In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP/MXR/ABCP/ABCG2)
Q83390482In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance
Q37128654Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice
Q42549809Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202).
Q37788732Level of evidence for therapeutic drug monitoring of taxanes
Q34095952Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.
Q35781414Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.
Q38756385Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.
Q91644097Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
Q35584977Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism
Q90298807Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure
Q38130410PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.
Q53272686Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.
Q36441485Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management
Q37684533Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy
Q27006783Pharmacogenomics of breast cancer therapy: an update
Q36304316Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes
Q37187663Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.
Q37686610Population-based differences in treatment outcome following anticancer drug therapies.
Q90568559Single-nucleotide polymorphisms and mRNA expression of CYP1B1 influence treatment response in triple negative breast cancer patients undergoing chemotherapy
Q34390370Taxane pathway
Q58697844VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters